Author

Sven deVos

Observed names: DeVos, S, DeVos, Sven, Sven DeVos, Sven Devos

Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center

Observed institutions: Cedars-Sinai Medical Center, University of California, Los Angeles, MemorialCare Long Beach Medical Center, Long Beach Medical Center, UCLA Jonsson Comprehensive Cancer Center

OpenAlex ID: A5111962160

Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells

2004 · Carsten Müller-Tidow, Björn Steffen, et al. · Molecular and Cellular Biology · 303

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

2013 · Sally Arai, Michelle Fanale, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 139

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

2023 · Andrew D. Zelenetz, Leo I. Gordon, et al. · Journal of the National Comprehensive Cancer Network · 132

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

2008 · Eric D. Hsi, Sin-Ho Jung, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 117

Herpesvirus 8 Inclusions in Primary Effusion Lymphoma

1999 · Jonathan W. Said, I. Peter Shintaku, et al. · Archives of Pathology & Laboratory Medicine · 76

Identifying progression‐associated genes in adult T‐cell leukemia/lymphoma by using oligonucleotide microarrays

2004 · Kunihiro Tsukasaki, Sakae Tanosaki, et al. · International Journal of Cancer · 38

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

2016 · Laurie H Sehn, Michael Hallek, et al. · Blood · 31

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

2014 · Jennifer R. Brown, Peter Hillmen, et al. · Blood · 30

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025

2025 · Andrew D. Zelenetz, Leo I. Gordon, et al. · Journal of the National Comprehensive Cancer Network · 22

Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas

2020 · Nina D. Wagner-Johnston, Stephen J. Schuster, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology

2026 · Andrew D. Zelenetz, Leo I. Gordon, et al. · Journal of the National Comprehensive Cancer Network · 1

Updated efficacy including genetic subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously-treated CLL/SLL

2015 · Pagel, John, Brown, Jennifer, et al. · eScholarship (California Digital Library)

Randomized Comparison of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: Results From the Phase Iii Pcyc-1112 Resonate(™) Trial

2014 · Hillmen, P, Brown, JR, et al. · eScholarship (California Digital Library)

Regulated Expression of Activated Notch 1 during Embryonic Stem Cell Differentiation Preserves Multipotential Progenitors and Promotes Erythroid Cell Fate.

2004 · Uma Ganapati, Lynne A. Bui, et al. · Blood

Works count: 16

Citation count: 909

H-index: 10

I10-index: 10